DOCSLIB.ORG

BD Rhapsody™ T-Cell Targeted Panel (Human) Targeted Human T-Cell Gene Panel for the BD Rhapsody Single-Cell Analysis System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BD Rhapsody™ T-Cell Targeted Panel (Human) Targeted Human T-Cell Gene Panel for the BD Rhapsody Single-Cell Analysis System BD Rhapsody™ T-Cell Targeted Panel (Human) Targeted human T-cell gene panel for the BD Rhapsody Single-Cell Analysis System • Validated panel focuses on genes relevant to T-cell biology understanding of T-cell biology will appreciate a cost-efficient • Single-cell expression profiling complements solution suited for studying autoimmune disorders, allergy, traditional FACS infection, cancer, metabolic inflammation and more. • Reproducible assay empowers numbers applications Expertly designed panels give you the right genes The mammalian immune system is a complicated defense Drawing from BD’s 40 years of experience in immunology and network against foreign invaders, such as pathogens, FACS, the panel content was chosen to include relevant FACS environmental antigens and cancer. T cells are integral members phenotypic markers known to identify various T-cell of this system, conducting intracellular surveillance, cellular subpopulations, as well as the genes involved in proliferation, destruction, and immune system stimulation and memory. activation signaling, and metabolism. While the panel content Therefore, T cells are subject to complex regulation and overlaps with genes in the BD Rhapsody Immune Response Panel, differentiation, sometimes yielding very rare the BD Rhapsody T-Cell Targeted Panel assay is tailored for T-cell functional subtypes. biology, and allows researchers to customize the panel with The BD Rhapsody™ T-Cell Targeted Panel (Human) provides a user-selected genes. streamlined assay for single-cell research of T cells with the BD Easier, comprehensive libraries for sequencing Rhapsody Single-Cell Analysis System. The panels provide a snapshot of T-cell gene expression, to complement traditional The BD Rhapsody T-Cell Targeted Panel (Human) utilizes techniques like FACS. Researchers interested in advancing multiplex PCR for detecting 259 genes chosen for T-cell profiling. After cells are lysed in the BD Rhapsody Cartridge, beads containing captured mRNA are magnetically retrieved for cDNA Universal oligo bead Univ CL UMI dT cDNA synthesis. Included primers are used for gene-specific nested PCR BD Rhapsody T-Cell for library construction. The final PCR amplification products for Multiplex PCR 1 PCR 1 primer Universal oligo Univ = Universal sequencing contain sequencing adapters, a cell label, unique sequence Univ CL UMI dT cDNA UMI = Unique molecular index (UMI) and up to 400 bp of the 3’ end of the molecular BD Rhapsody T-Cell index Multiplex PCR 2 PCR 2 primer target gene. Assay products can be sequenced on Illumina MiSeq, CL = Cell label Library forward primer dT = oligo(dT) NextSeq, HiSeq2500 and HiSeq4000 sequencers. Univ CL UMI dT cDNA Final amplification Library reverse primer Read 1 Sequencing adapter Univ CL UMI dT cDNA Sequencing adapter & library index Read 2 Figure 1. cDNA synthesis and library construction chemistry using the BD Rhapsody T-Cell Targeted Panel (Human). A Custom panels let you design your own targets Analysis of resting CD3 T cells with BD Rhapsody T-Cell Targeted Panel For exploring genes beyond the panel, the BD Rhapsody T-Cell ● (1) CD4 Effector/Effector Memory (40.6%) Targeted Panel allows customization by adding user-defined ● (2) CD4 Naive (27.1%) ● (3) CD4 Naive/Central Memory (0.7%) genes. Select up to 100 additional genes as a BD Rhapsody ● (4) CD8 Central Memory (5.7%) Supplemental Panel. Using BD’s primer design software, primers ● (5) CD8 Effector/Effector Memory (13.3%) ● (6) CD8 Naive (9.5%) for supplemental gene targets are designed to be compatible ● (7) Treg (1.0%) with pre-designed base panels. Supplemental primers are ● (8) gamma delta T (2.1%) shipped to you and combined with the BD Rhapsody T-Cell Targeted Panel for library preparation. Expression profiling of the single cell To show the performance of the BD Rhapsody T-Cell Targeted Panel (Human), CD3 T cells were isolated from cryopreserved PBMCs and stimulated overnight with anti-CD3/28 (activated T) or isolated immediately before use (resting T). 3,436 cells in the resting T-cell sample and 5,115 cells in the activated T-cell B CCR7 CD4 LEF1 IL7R IL2RB CCL5 GZMK CD8A PRF1 FOXP3 sample were profiled using the BD Rhapsody system T-Cell 1 2 Targeted Panel. In addition to differentiation of commonly 3 4 observed CD4 and CD8 naïve, effector and memory T-cell 5 6 subsets, rarer populations, such as gamma delta T cells, are 7 identified with the panel. 8 0 0.5 0 0.5 1 0 0.5 1 0 0.5 1 0 0.5 1 0 1 0 0.5 1 0 0.5 1 0 0.5 0 0.5 1 log 10(number of molecules) Table 1: Example genes by category C Pathway # of genes in panel Analysis of activated CD3 T cells with BD Rhapsody T-Cell Targeted Panel CD marker 25 Cell type marker 21 Chemokine 12 Chemokine receptor 15 Cytokine 11 Cytokine receptor 8 Interleukin 29 Other* 138 (1) CD4 Effector/Effector Memory (30.6%) * Apoptosis regulator; cell adhesion; cell cycle & proliferation; effector molecule; enzyme; ● ● (2) CD4 Naive/Central Memory (32.8%) growth factor; Immune checkpoint; Immune receptor; integrin; kinase; metabolism; ● (3) CD8 Cytotoxic/Effector Memory (12.5%) MHC class I or II; NK cell receptor; nuclear receptor; stress response; toll like receptor; ● (4) CD8 Naive/Central Memory (12.5%) transcription factor; transporter ● (5) Exhausted CD8 (5.2%) ● (6) Treg (4.6%) ● (7) gamma delta T (1.6%) Table 2: BD Rhapsody T-Cell Targeted Panel metrics Total reads recommended per cell For cell type identification 2K D IL7R CCR7 CD4 TNF IL2 CD8A IFNG LAG3 PRDM1 FOXP3 For direct comparison across samples 20K 1 2 # of genes in panel 259 3 4 5 6 Learn more about the power of targeted single-cell analysis 7 0 1 0 1 0 0.5 1 0 1 2 0 2 0 1 0 2 0 1 0 0.5 0 1 The BD Rhapsody T-Cell Targeted Panel shows validated, log 10(number of molecules) reproducible and reliable dissection of T-cell subsets, useful for Figure 2. Example data of the BD Rhapsody T-cell panel. (a) tSNE projection of exploring cell types in a wide variety of applications. Contact us 3,436 resting CD3+ T cells, annotated by cell type. (b) Box plots of marker gene to learn what this panel and the BD Rhapsody system can do for expression for each major cell type, annotated in Figure 2a. (c) tSNE project of 5, your research. 115 activated CD3+ T cells, annotated by cell type. (d) Box plots of marker gene expression for each major cell type annotated in Figure 2c. bd.com/genomics For Research Use Only. Not for use in diagnostic or therapeutic procedures. Trademarks are the property of their respective owners. © 2017 BD. BD, the BD Logo and all other trademarks are property of Becton, Dickinson and Company. BDGM1016 Rev. 2.
Load more

Recommended publications
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • Assessing the Tumor Microenvironment by Recovery of Immune Receptor V(D)J Recombination Reads from Tumor Specimen Exome Files
    Assessing the Tumor Microenvironment by Recovery of Immune Receptor V(D)J Recombination Reads from Tumor Specimen Exome Files George Blanck, Ph.D. Professor, Molecular Medicine Morsani College of Medicine, USF Immunology Program, Moffitt Cancer Center (not for publication or public web page) Learning objectives: 1. To appreciate the availability of T-cell receptor recombination information from tumor specimen DNA samples. 2. To understand the correlation between T-cell receptor recombinations, in tumor specimen DNA, and other, clinically relevant information for bladder cancer and kidney renal cell carcinoma. 3. To understand the importance of HLA alleles in assessing the impact of T-cell receptor recombinations from tumor specimen DNA. Fig. 1. Immune receptor genes recombine during development to generate many different receptor molecules among the B-cells and T- cells, throughout the body, through life, to bind many different antigens, including tumor antigens. Seven immune receptor genes total: • Three related to antibodies, not further discussed. • Two related to gamma-delta T-cells, not further discussed • Two required for alpha-beta T-cells, the subject of this presentation. Alpha-beta T-cells: • Most numerous. • Best understood, medically speaking. • Generally target peptide antigen, in the case of tumors, a mutant peptide. • The TRB part of the TRA/TRB receptor is considered most important in antigen binding. The tumor specimen and the exome • Surgically remove tumor, obtain DNA sequence (all exons = exome), for tumor mutations, which can guide therapy. • Other cells in the specimen, particularly T-cells. • The DNA representing the T-cell receptor can be identified above the tumor DNA “background”. Fig.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • A New Role for NKG2D Signaling in CD8 T Cells and Autoimmune
    A new role for NKG2D signaling in CD8+ T cells and autoimmune diabetes By Andrew P Trembath © 2019 Submitted to the graduate degree program in Microbiology, Molecular Genetics and Immunology, and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Mary A. Markiewicz Ph.D Wolfram R. Zückert Ph.D. Patrick E. Fields, Ph.D. Maria Kalamvoki Ph.D. Joe Lutkenhaus Ph.D Date Defended: 11/13/2019 ii The dissertation committee for Andrew Trembath certifies that this is the approved version of the following dissertation: A new role for NKG2D signaling in CD8+ T cells and autoimmune diabetes Chair: Mary A. Markiewicz, Ph.D. Date Approved: 12/19/2019 iii Abstract The demands placed on the immune system are immense and highly complex. It must protect the body against untold threats while maintaining a balance between immune defense and autoimmune damage. One major player in immune recognition is the receptor Natural-Killer- Group-2-Member-D (NKG2D), best known for its expression on natural killer (NK) cells and CD8+ T cells, where it recognizes NKG2D ligands expressed by stressed cells following viral infection or cancerous transformation. NKG2D is most well studied for its role in tumor immunity, for which NKG2D based therapies are currently being developed clinically. Despite this, it is apparent that NKG2D has other poorly understood immune regulating functions, such as its implicated involvement in type 1diabetes and other autoimmune disorders. However, the mechanism by which NKG2D signaling affects diabetes has been unclear. We therefore sought to further clarify the role NKG2D plays in autoimmune diabetes development.
    [Show full text]
  • Toll and Toll-Like Receptor Signalling in Development Niki Anthoney*, Istvan Foldi‡ and Alicia Hidalgo§
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repository of the Academy's Library © 2018. Published by The Company of Biologists Ltd | Development (2018) 145, dev156018. doi:10.1242/dev.156018 DEVELOPMENT AT A GLANCE Toll and Toll-like receptor signalling in development Niki Anthoney*, Istvan Foldi‡ and Alicia Hidalgo§ ABSTRACT signalling and discuss how this signalling pathway regulates various The membrane receptor Toll and the related Toll-like receptors aspects of development across species. (TLRs) are best known for their universal function in innate immunity. KEY WORDS: Toll, Tol-1, TLR, TIR-NBS-LRR, Sarm, MyD88, NF-κB, However, Toll/TLRs were initially discovered in a developmental Dorsal, Wek, JNK, FoxO, Cell death, Cell survival, Cell fate, context, and recent studies have revealed that Toll/TLRs carry out Cell proliferation, Structural plasticity, Signalling previously unanticipated functions in development, regulating cell fate, cell number, neural circuit connectivity and synaptogenesis. Introduction Furthermore, knowledge of their molecular mechanisms of action is The Drosophila gene Toll is possibly the only gene associated with expanding and has highlighted that Toll/TLRs function beyond the two Nobel Prizes: it was discovered as one of the key genes canonical NF-κB pathway to regulate cell-to-cell communication and determining body plan, and was later rediscovered for its role in signalling at the synapse. Here, we provide an overview of Toll/TLR underlying innate immunity (leading to the 1995 and 2011 Nobel Prizes in Physiology or Medicine, respectively). Searches for Toll NeuroDevelopment Group, School of Biosciences, University of Birmingham, homologues led to the identification of Toll-like receptor (TLR) Birmingham B15 2TT, UK.
    [Show full text]
  • The Immune System
    Chapter 43 The Immune System Lecture Outline Overview: Reconnaissance, Recognition, and Response • An animal must defend itself against pathogens, infectious agents that cause disease. o Viruses, bacteria, protists, and fungi infect a wide range of animals, including humans. • Animals fight back in various ways. o Immune cells patrol the body fluids of animals, seeking out and destroying foreign cells. o Responses to infection include proteins that punch holes in bacterial membranes or block viruses from entering body cells. • Immune systems help animals to avoid or limit many infections. o External barriers, formed by the skin or shell, provide an obstacle to microbes. o Chemical secretions that trap or kill microbes guard the body’s entrances and exits. o The internal defenses include macrophages and other phagocytic cells that ingest and destroy pathogens. • An animal’s immune system must detect foreign particles and tissues that invade the body, distinguishing self from nonself. • To identify pathogens, animal immune systems use receptors that specifically bind molecules from foreign cells or viruses. • Two general strategies for molecular recognition form the basis for innate and acquired immunity. • Innate immunity is common to all animals. • Innate immune responses are active immediately upon infection and are the same whether or not the pathogen has been encountered previously. • Innate immunity includes the barrier defenses (for example, skin) as well as defenses that combat pathogens after they enter the body. • The activation of many of these internal defenses relies on the recognition of pathogens. o Innate immune cells produce a small, preset group of receptor proteins that accomplish this recognition.
    [Show full text]
  • Mast Cell Signaling: the Role of Protein Tyrosine Kinase Syk, Its Activation and Screening Methods for New Pathway Participants
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 584 (2010) 4933–4940 journal homepage: www.FEBSLetters.org Review Mast cell signaling: The role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants Reuben P. Siraganian *, Rodrigo O. de Castro, Emilia A. Barbu, Juan Zhang Receptors and Signal Transduction Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bldg. 49, Rm. 1A16, Bethesda, MD 20892, USA article info abstract Article history: The aggregation by antigen of the IgE bound to its high affinity receptor on mast cells initiates a Received 27 July 2010 complex series of biochemical events that result in the release of inflammatory mediators. The Accepted 3 August 2010 essential role of the protein tyrosine kinase Syk has been appreciated for some time, and newer Available online 7 August 2010 results have defined the mechanism of its activation. The use of siRNA has defined the relative con- tribution of Syk, Fyn and Gab2 to signaling and has made possible a screening study to identify pre- Edited by Israel Pecht viously unrecognized molecules that are involved in these pathways. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. Keywords: Mast cell FceRI signal transduction Syk Fyn Gab2 Phosphatase 1. Introduction The a-chain binds the Fc portion of IgE at ratio of 1:1 while the b- and c-chains contain ITAMs in their cytoplasmic domains. Be- The activation of mast cells or basophils initiates a series of bio- cause FceRI has no intrinsic enzymatic activity, the activation of chemical events which result in the release of biologically active non-receptor protein tyrosine kinases are essential for cell activa- mediators that cause allergic reactions.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint
    cells Article Examining the Relationship between Circulating CD4− CD8− Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy—Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma Sabino Strippoli 1 , Annarita Fanizzi 2 , Antonio Negri 3, Davide Quaresmini 1, Annalisa Nardone 2, Andrea Armenio 4, Angela Monica Sciacovelli 1, Raffaella Massafra 2, Ivana De Risi 1, Giacoma De Tullio 3, Anna Albano 1 and Michele Guida 1,* 1 Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy; [email protected] (S.S.); [email protected] (D.Q.); [email protected] (A.M.S.); [email protected] (I.D.R.); [email protected] (A.A.) 2 Radiotherapy Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy; [email protected] (A.F.); [email protected] (A.N.); [email protected] (R.M.) 3 Unit of Hematology and Cell Therapy, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy; [email protected] (A.N.); [email protected] (G.D.T.) Citation: Strippoli, S.; Fanizzi, A.; 4 Department of Plastic Surgery, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy; Negri, A.; Quaresmini, D.; Nardone, A.; [email protected] Armenio, A.; Sciacovelli, A.M.; * Correspondence: [email protected]; Tel.: +39-08-0555-5136 Massafra, R.; De Risi, I.; De Tullio, G.; et al. Examining the Abstract: Background: The role of circulating CD4−/CD8− double-negative T cells (DNTs) in the Relationship between Circulating immune response to melanoma is poorly understood, as are the effects of checkpoint inhibitors on CD4− CD8− Double-Negative T T cell subpopulations.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Regulatory T Cell Research
    Regulatory T cell research Unique kits for cell isolation Harmonized cell culture and expansion tools Convenient functional assay tools Germany/Austria/ Benelux France Nordics and Baltics South Korea Switzerland Miltenyi Biotec B.V. Miltenyi Biotec SAS Miltenyi Biotec Norden AB Miltenyi Biotec Korea Co., Ltd Reliable flow cytometry analysis Miltenyi Biotec GmbH Schipholweg 68 H 10 rue Mercoeur Scheelevägen 17 Arigi Bldg. 8F Friedrich-Ebert-Straße 68 2316 XE Leiden 75011 Paris, France 223 70 Lund 562 Nonhyeon-ro 51429 Bergisch Gladbach The Netherlands Phone +33 1 56 98 16 16 Sweden Gangnam-gu Germany [email protected] Fax +33 1 56 98 16 17 [email protected] Seoul 06136, South Korea Phone +49 2204 8306-0 Customer service [email protected] Customer service Sweden Phone +82 2 555 1988 Fax +49 2204 85197 The Netherlands Phone 0200-111 800 Fax +82 2 555 8890 [email protected] Phone 0800 4020120 Italy Fax 046-280 72 99 [email protected] Fax 0800 4020100 Miltenyi Biotec S.r.l. Customer service Denmark USA/Canada Customer service Belgium Via Persicetana, 2/D Phone 80 20 30 10 Spain Miltenyi Biotec Inc. Phone 0800 94016 40012 Calderara di Reno (BO) Fax +46 46 280 72 99 Miltenyi Biotec S.L. 2303 Lindbergh Street Fax 0800 99626 Italy Customer service C/Luis Buñuel 2 Auburn, CA 95602, USA Customer service Luxembourg Phone +39 051 6 460 411 Norway, Finland, Iceland, Ciudad de la Imagen Phone 800 FOR MACS Phone 800 24971 Fax +39 051 6 460 499 and Baltic countries 28223 Pozuelo de Alarcón (Madrid) Phone +1 530 888 8871 Fax 800 24984 [email protected] Phone +46 46 280 72 80 Spain Fax +1 877 591 1060 Fax +46 46 280 72 99 Phone +34 91 512 12 90 [email protected] China Japan Fax +34 91 512 12 91 Miltenyi Biotec Technology & Miltenyi Biotec K.K.
    [Show full text]